InsiderSignalSign in

← Insider buys

IMVT

Immunovant, Inc. · Healthcare

Insiders bought $350.0M of Immunovant, Inc. in the last 12 months

1 insider bought on 1 day.

$350.0MBought, 12 mo

$15.5MSold, 12 mo

$5.9BMarket cap

IMVT over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

Roivant Sciences Ltd.Director and 10% owner · 1 day$350.0M

IMVT after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

139 insider filings since 2020, newest first

Eva Renee Barnett · CFO

$94K−1.0%Oct 18

Eva Renee Barnett · CFO

$153K−2.0%Oct 11

Peter Salzmann · CEO

Mark S. Levine · General Counsel

$105K−1.0%Aug 23

William L. Macias · Chief Medical Officer

$96K−1.0%Aug 23

Eva Renee Barnett · CFO

$120K−1.0%Aug 23

Julia G. Butchko · Chief Development Officer

$96K−1.0%Aug 23

Peter Salzmann · CEO

$480K−1.0%Aug 23

Jay S Stout · CTO

$78K−2.0%Jul 26

Michael Geffner · Chief Medical Officer

$96K−2.0%Jul 26

Mark S. Levine · General Counsel

$111K−1.0%Jul 26

Mark S. Levine · General Counsel

$74K−1.0%Jul 19

William L. Macias · Chief Medical Officer

$90K−1.0%Jul 19

Eva Renee Barnett · CFO

$93K−1.0%Jul 19

Julia G. Butchko · Chief Development Officer

$85K−1.0%Jul 19

Peter Salzmann · CEO

$258K−1.0%Jul 19

Eva Renee Barnett · CFO

$133K−1.0%Jul 10

Julia G. Butchko · Chief Development Officer

Peter Salzmann · CEO

Eva Renee Barnett · CFO

$120K−1.0%May 24

Peter Salzmann · CEO

$479K−2.0%May 24

Julia G. Butchko · Chief Development Officer

$96K−1.0%May 24

William L. Macias · Chief Medical Officer

$96K−1.0%May 24

Mark S. Levine · General Counsel

$96K−1.0%May 24

Jay S Stout · CTO

$209K−5.0%Apr 26

Michael Geffner · Chief Medical Officer

$94K−2.0%Apr 26

Mark S. Levine · General Counsel

$115K−1.0%Apr 26

Mark S. Levine · General Counsel

$286K−3.0%Apr 19

William L. Macias · Chief Medical Officer

$241K−2.0%Apr 19

Eva Renee Barnett · CFO

$356K−3.0%Apr 19

Julia G. Butchko · Chief Development Officer

$294K−2.0%Apr 19

Peter Salzmann · CEO

$990K−3.0%Apr 19

Eva Renee Barnett · CFO

$115K−1.0%Apr 10

Julia G. Butchko · Chief Development Officer

Peter Salzmann · CEO

Eva Renee Barnett · CFO

$106K−1.0%Feb 23

Mark S. Levine · General Counsel

$77K−1.0%Feb 23

William L. Macias · Chief Medical Officer

$80K−1.0%Feb 23

Julia G. Butchko · Chief Development Officer

$78K−1.0%Feb 23

Peter Salzmann · CEO

$486K−1.0%Feb 23

Mark S. Levine · General Counsel

$115K−1.0%Jan 29

Michael Geffner · Chief Medical Officer

$383K−10.0%Jan 29

Eva Renee Barnett · CFO

$147K−1.0%Jan 12

Julia G. Butchko · Chief Development Officer

Peter Salzmann · CEO

Andrew J. Fromkin · Director

$491K−12.0%Dec 5

Atul Pande · Director

$491K−11.0%Dec 5

George Migausky V · Director

$505K−10.0%Dec 5

Peter Salzmann · CEO

$532K−2.0%Nov 24

Eva Renee Barnett · CFO

$133K−1.0%Nov 24

Newer filings Older filings

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.